How Mounjaro's mechanism of action produces weight loss

You've read that Mounjaro works 'differently', here's precisely what that means

Most people who look up Mounjaro's mechanism of action already know it's something to do with gut hormones. What's harder to picture is why two receptors matter more than one. Let's start where the medicine starts: in your gut, after a meal.

When you eat, your intestinal cells release hormones called incretins. Two of them are particularly relevant here. GLP-1 (glucagon-like peptide-1) travels to the brain and signals fullness; it also tells the pancreas to release insulin in proportion to what you've eaten, and it slows down gastric emptying so food moves more gradually into the small intestine. GIP (glucose-dependent insulinotropic polypeptide) works alongside GLP-1, contributing its own appetite-suppressing signals and enhancing the metabolic response to a meal through slightly different neural and cellular pathways.

In people with obesity, these hormonal signals are often blunted. The satiety cue arrives late or quietly. Food moves too fast. The feedback loop that tells you to stop eating takes longer to fire. Tirzepatide, the active molecule in Mounjaro, is a synthetic peptide engineered to bind tightly to both the GIP and GLP-1 receptors and activate them with a potency that natural hormones don't reach. The result is a much stronger, more sustained version of the satiety and metabolic signals the body already uses. You can read more about the receptor-level detail on our tirzepatide GIP and GLP-1 mechanism page.

This is different from earlier GLP-1 medicines, which target only the GLP-1 pathway. Activating two complementary pathways appears to produce additive effects on appetite and weight, which is the reason trial results for tirzepatide have consistently exceeded those of single-receptor agents, and our Mounjaro action page goes into greater depth on how those two pathways combine to produce the effects seen in practice.

What the dual mechanism actually does to hunger, fullness and food intake

If you've ever been genuinely not hungry at a mealtime (not dieting, not distracted, just not interested in food) that's a rough approximation of what tirzepatide shifts your baseline towards. It doesn't eliminate hunger entirely, and it doesn't work the same way for everyone, but the mechanism is well understood.

Gastric emptying slows. This is measurable: food stays in the stomach longer, which prolongs the physical sensation of fullness and flattens the blood-sugar spike that normally follows a carbohydrate-rich meal. The brain receives sustained signals from both GIP and GLP-1 receptors in regions associated with appetite regulation, particularly the hypothalamus. Those signals reduce the drive to eat and, over time, tend to shift preferences away from energy-dense foods, an effect researchers think may relate partly to GIP's action on reward pathways, though that strand of the science is still being clarified.

The practical result in clinical trials was striking. In the SURMOUNT-1 study, adults with obesity taking tirzepatide lost an average of around 20–21% of body weight over 72 weeks at the highest dose, with some participants losing considerably more, findings published in the New England Journal of Medicine and later reviewed by NICE as part of its tirzepatide appraisal. In a subsequent head-to-head comparison (SURMOUNT-5), tirzepatide produced greater average weight loss than semaglutide 2.4mg over the same period.

It's worth understanding that the mechanism also underlies the side-effect profile. Slowing gastric emptying is what produces nausea and, for some people, vomiting or constipation, particularly in the early weeks or after a dose increase. Those effects are a direct consequence of the very mechanism that reduces appetite. They typically settle as the body adjusts. A fuller breakdown of what to expect is covered on the Mounjaro information page.

Why the mechanism shapes the licensed dose schedule, and what that means for you

If you feel some frustration at having to start on a low dose when you're ready to get going, that's completely understandable. The titration schedule exists precisely because of how the mechanism works.

Tirzepatide's action on gastric motility is dose-dependent: stronger at higher doses, which is where the weight-loss effect is greatest, but also where GI side effects are most likely if the body hasn't had time to adapt. The licensed schedule in the UK starts at 2.5 mg, a dose whose job is to let your gut adjust to the slower emptying and stronger satiety signals, not to produce significant weight change. Doses are then increased, typically in four-week steps, by a prescriber who reviews your response and tolerance at each stage. The duration of tirzepatide's action between weekly injections also matters clinically: the half-life of around five days means levels don't drop to zero between doses, which is what allows a once-weekly injection to maintain a steady effect rather than producing peaks and troughs.

Because it's a prescription-only medicine, the dose you reach, how quickly you get there, and when you might stop are all decisions made between you and your prescriber. The tirzepatide overview covers the licensed strengths and what clinical assessment involves. If you're already on treatment and wondering about how the mechanism interacts with other medicines, the Mounjaro and Pepto-Bismol page is one example of where that kind of question is addressed; your prescriber or the patient information leaflet is always the right first call for specific queries.

For a broader look at what treatment involves and whether it might suit you, the weight-loss treatment overview is a good starting point. And if you're already weighing up the options, checking your eligibility with one of our prescribers costs nothing and takes a few minutes. The NHS's own patient-level guidance on tirzepatide is also worth reading alongside anything you find here: the NHS tirzepatide page covers the medicine's action, common side effects and when to seek help in clear, reliable language.